Admittance Technologies is committed to improving the quality of life of patients with heart disease through innovative electrical engineering solutions. We have developed a novel and proprietary volume measurement technology called CardioVol(tm). Our goal is to reduce heart failure hospitalizations through the integration of CardioVol(tm) into implantable devices that connect with shocking coil leads, allowing these devices to provide real time ventricular blood volume data. CardioVol(tm) enabled devices operate at extremely low power and can monitor preload directly (via End Diastolic Volume), allowing physicians and patients to monitor actionable hemodynamic data without a separate implant. These data can be used to adjust medication (telemedicine) and possibly prevent acute heart failure hospitalizations.